文献速递精神分裂症与精神病性障碍

氯氮平联合阿立哌唑与精神科再住院风险的全国队列研究

Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.
PubMed 文献 · JAMA Psychiatry · 2019-01-01

结果显示氯氮平联合阿立哌唑再住院风险最低,优于氯氮平单药(HR 0.86,95%CI 0.79-0.94);任何多药联合较单药风险低7%-13%。

要点

  • 氯氮平联合阿立哌唑再住院风险最低,较氯氮平单药低14%(HR 0.86)。
  • 保守分析排除短于90天的多药期间,联合组仍优于单药(HR 0.82)。
  • 任何抗精神病药多药联合较单药再住院风险低7%-13%。

核心结论

  • 氯氮平联合阿立哌唑与最低的精神科再住院风险相关,优于氯氮平单药。
  • 某些类型的抗精神病药多药联合在精神分裂症维持治疗中可能可行。
  • 现行指南应修改一概不推荐所有抗精神病药多药联合的 categorical 建议。

研究设计与样本

  • 采用个体内分析以减少选择偏倚,以精神科再住院风险作为复发标志。
  • 数据分析时间为2018年4月24日至6月15日。

主要发现

  • 氯氮平联合阿立哌唑在全队列中再住院风险最低,优于氯氮平单药,差异14%(HR 0.86;95%CI 0.79-0.94)。
  • 保守定义的多药联合分析(排除短于90天期间)差异18%(HR 0.82;95%CI 0.75-0.89;P < .001)。
  • 首发精神分裂症患者中,氯氮平联合阿立哌唑 vs 氯氮平单药的差异更大:所有多药期间分析差异22%(HR 0.78;95%CI 0.63-0.96),保守分析差异23%(HR 0.77;95%CI 0.63-0.95)。
  • 总体水平上,任何抗精神病药多药联合较任何单药再住院风险低7%至13%(HR范围0.87;95%CI 0.85-0.88至HR 0.93;95%CI 0.91-0.95;P < .001)。

关键数值与推荐

  • 氯氮平联合阿立哌唑 vs 氯氮平单药:HR 0.86(95%CI 0.79-0.94)。
  • 保守多药分析(排除短于90天):HR 0.82(95%CI 0.75-0.89;P < .001)。
  • 首发患者所有多药期间分析:HR 0.78(95%CI 0.63-0.96)。
  • 首发患者保守多药分析:HR 0.77(95%CI 0.63-0.95)。
  • 任何多药 vs 任何单药:HR范围0.87(95%CI 0.85-0.88)至0.93(95%CI 0.91-0.95),P < .001。

临床怎么用

  • 对于单药治疗不足以控制症状的精神分裂症维持期患者,可考虑氯氮平联合阿立哌唑。
  • 不应一概否定所有抗精神病药多药联合,需根据具体组合评估可行性。
  • 添加治疗常在单药控制不佳时启动,多药联合的效应量可能被低估。

局限性

  • 观察性研究设计,虽采用个体内分析,仍可能存在残余混杂。
  • 多药联合的效应量可能因添加治疗时机而被低估。
  • 结果不表明所有类型的多药联合均有益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The effectiveness of antipsychotic polypharmacy in schizophrenia relapse prevention is controversial, and use of multiple agents is generally believed to impair physical well-being. OBJECTIVE: To study the association of specific antipsychotic combinations with psychiatric rehospitalization. DESIGN, SETTING, AND PARTICIPANTS: In this nationwide cohort study, the risk of psychiatric rehospitalization was used as a marker for relapse among 62 250 patients with schizophrenia during the use of 29 different antipsychotic monotherapy and polypharmacy types between January 1, 1996, and December 31, 2015, in a comprehensive, nationwide cohort in Finland. We conducted analysis of the data from April 24 to June 15, 2018. Rehospitalization risks were investigated by using within-individual analyses to minimize selection bias. MAIN OUTCOMES AND MEASURES: Hazard ratio (HR) for psychiatric rehospitalization during use of polypharmacy vs during monotherapy within the same individual. RESULTS: In the total cohort, including 62 250 patients, 31 257 individuals (50.2%) were men, and the median age was 45.6 (interquartile range, 34.6-57.9) years. The clozapine plus aripiprazole combination was associated with the lowest risk of psychiatric rehospitalization in the total cohort, being superior to clozapine, the monotherapy associated with the best outcomes, with a difference of 14% (HR, 0.86; 95% CI, 0.79-0.94) in the analysis including all polypharmacy periods, and 18% in the conservatively defined polypharmacy analysis excluding periods shorter than 90 days (HR, 0.82; 95% CI, 0.75-0.89; P < .001). Among patients with their first episode of schizophrenia, these differences between clozapine plus aripiprazole vs clozapine monotherapy were greater (difference, 22%; HR, 0.78; 95% CI, 0.63-0.96 in the analysis including all polypharmacy periods, and difference, 23%; HR, 0.77; 95% CI, 0.63-0.95 in the conservatively defined polypharmacy analysis). At the aggregate level, any antipsychotic polypharmacy was associated with a 7% to 13% lower risk of psychiatric rehospitalization compared with any monotherapy (ranging from HR, 0.87; 95% CI, 0.85-0.88, to HR, 0.93; 95% CI, 0.91-0.95; P < .001). Clozapine was the only monotherapy among the 10 best treatments. Results on all-cause and somatic hospitalization, mortality, and other sensitivity analyses were in line with the primary outcomes. CONCLUSIONS AND RELEVANCE: Combining aripiprazole with clozapine was associated with the lowest risk of rehospitalization, indicating that certain types of polypharmacy may be feasible in the treatment of schizophrenia. Because add-on treatments are started when monotherapy is no longer sufficient to control for worsening of symptoms, it is likely that the effect sizes for polypharmacy are underestimates. Although the results do not indicate that all types of polypharmacy are beneficial, the current treatment guidelines should modify their categorical recommendations discouraging all antipsychotic polypharmacy in the maintenance treatment of schizophrenia.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Tiihonen J, Taipale H, Mehtälä J, et al. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. JAMA Psychiatry. 2019. PMID: 30785608. doi:10.1001/jamapsychiatry.2018.4320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。